Stock market announcement archive

April 3, 2024
Bergen, Norway, 3rd April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has successfully reached the target for pilot production of the Sencell sensor. Reports show a breakthrough, and this will pave the way for the automated production by end of Q2 as scheduled. Reference […]
Read more
March 21, 2024
Bergen, Norway, March 21st, 2024: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the European Patent Office (EPO) has notified that they will grant for a new patent to Lifecare. Reference is made to stock exchange notification November 8th, 2023, that EPO intended […]
Read more
March 6, 2024
Today starts the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2024) in Firenze. Lifecare will be represented at the conference and have been accepted to present three poster presentations. ATTD is a leading international diabetes technology forum where clinicians, diabetes care providers, researchers, industries, start-up, investors, reimbursement authorities, regulators and people with […]
Read more
March 5, 2024
Bergen, Norway, 5 March 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare has placed the purchase order for a cleanroom. Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of August 20th, 2023 and later […]
Read more
February 26, 2024
Lifecare AS will present Q4 2023 financial and operational status in a webcast Tuesday 27 February. The webcast will be for all shareholders and interested parties at 12:00 – 12:45 CET. Lifecare’s CEO Joacim Holter presents the company’s Q4 report followed by a Q&A session where Holter will answer questions submitted in advance. Questions in […]
Read more
February 21, 2024
Bergen, Norway, February 21st, 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces today that the Board of Directors has decided to prepare for submitting application for listing of Lifecare’s shares at the main list of Oslo Stock Exchange (OSE), transferring from the current listing […]
Read more
February 14, 2024
Bergen, Norway, 14 February 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has successfully finished the first and important step of software implementation and coding for the upcoming automated pilot production. In addition to this Lifecare has received confirmation of delivery of essential equipment. Reference […]
Read more
February 1, 2024
Bergen, Norway, 1 February 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has appointed Torsten Ernst as Production Manager effective 1 March 2024. This appointment will strengthen our production team. Ernst is an industry specialist with a track record in making new solutions manufacturable, and […]
Read more
January 23, 2024
Bergen, Norway, 23 January 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has appointed Renete Kaarvik as Chief Financial Officer effective 1 Mai, 2024. Kaarvik joins Lifecare from the position as Global Finance Officer at Grieg Seafood ASA, a position she has held for close […]
Read more
January 9, 2024
Bergen, Norway, January 9th, 2024: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare Laboratory (Mainz, Germany) has received the official documentation for ISO 13485 certification. Reference is made to Lifecare’s stock exchange notification 27th of November 2022 when the ISO 13495 […]
Read more